Jubilant Pharmova
Jubilant Pharmova Share Price Chart
Jubilant Pharmova last traded at ₹957.50 (2026-10-13). Over the past month the stock moved -6.7%, three months the stock moved -2.8%, year the stock moved -13.2%. Its closing range over 52 weeks is ₹817.45 – ₹1,128.95, with the latest close 15.2% below the high.
Closing prices up to 2026-10-13.
About Jubilant Pharmova
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]
Business Segments & Revenue Contribution 9MFY24[1][2] a) Radiopharma (~44%): Radiopharmaceuticals (including radiopharmacies)The company is the #3 radiopharmaceutical manufacturer in the US and has the #2 network in the US with 46 radiopharmacies. In 9MFY24, sale of Mertiatide, Sulfur colloid) and Ruby-Fill did very well. RUBY-FILL is a cardiac imaging product. Company plans to maintain its leadership position in North America.[3]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Jubilant Pharmova reported sales of ₹2,229.00 crore (+17.3%) and net profit of ₹56.00 crore (-45.1%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 2,229 | 248.00 | 11.00 | 56.00 | 3.55 |
| Mar 2026 | 2,290 | 339.00 | 15.00 | 119.00 | 7.50 |
| Dec 2025 | 2,122 | 289.00 | 14.00 | 56.00 | 3.51 |
| Sep 2025 | 1,966 | 341.00 | 17.00 | 120.00 | 7.55 |
| Jun 2025 | 1,901 | 290.00 | 15.00 | 102.00 | 6.46 |
| Mar 2025 | 1,929 | 345.00 | 18.00 | 151.00 | 9.64 |
| Dec 2024 | 1,822 | 287.00 | 16.00 | 101.00 | 6.33 |
| Sep 2024 | 1,752 | 289.00 | 17.00 | 102.00 | 6.45 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +4.3% | +8.6% | +9.7% | +9.8% | +12.2% | +16.5% | +18.7% | +17.3% |
| Operating profit growth | +19.4% | +31.7% | +27.3% | +15.1% | +18.0% | +0.7% | -1.7% | -14.5% |
| Net profit growth | +64.5% | +53.0% | – | -78.8% | +17.6% | -44.6% | -21.2% | -45.1% |
| EPS growth | +64.5% | +51.1% | – | -78.7% | +17.1% | -44.5% | -22.2% | -45.0% |
| OPM % | 17.0% | 16.0% | 18.0% | 15.0% | 17.0% | 14.0% | 15.0% | 11.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Jubilant Pharmova reported sales of ₹8,280.00 crore (+14.5%) and net profit of ₹398.00 crore (-52.4%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 8,280 | 1,260 | 15.00 | 398.00 | 25.02 |
| Mar 2025 | 7,234 | 1,173 | 16.00 | 836.00 | 52.69 |
| Mar 2024 | 6,703 | 901.00 | 13.00 | 73.00 | 4.84 |
| Mar 2023 | 6,282 | 779.00 | 12.00 | -65.00 | -3.83 |
| Mar 2022 | 6,130 | 1,150 | 19.00 | 413.00 | 25.98 |
| Mar 2021 | 6,099 | 1,403 | 23.00 | 836.00 | 52.47 |
| Mar 2020 | 5,976 | 1,548 | 26.00 | 898.00 | 56.39 |
| Mar 2019 | 9,111 | 1,744 | 19.00 | 577.00 | 36.06 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +21.2% | -34.4% | +2.1% | +0.5% | +2.5% | +6.7% | +7.9% | +14.5% |
| Operating profit growth | +14.6% | -11.2% | -9.4% | -18.0% | -32.3% | +15.7% | +30.2% | +7.4% |
| Net profit growth | -9.0% | +55.6% | -6.9% | -50.6% | -115.7% | – | +1045.2% | -52.4% |
| EPS growth | -10.6% | +56.4% | -7.0% | -50.5% | -114.7% | – | +988.6% | -52.5% |
| OPM % | 19.0% | 26.0% | 23.0% | 19.0% | 12.0% | 13.0% | 16.0% | 15.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Jubilant Pharmova.
Get Free AI Stock Analysis FREE →Latest News
-
Jubilant Pharmova rises on getting nod to raise up to Rs 800 crore via NCDs
-
Jubilant Pharmova rises on getting nod to raise up to Rs 800 crore via NCDs
-
Jubilant Pharmova's arm to invest 94.5 million Canadian Dollar to double RUBY-FILL capacity
-
Jubilant Pharmova's arm to invest 94.5 million Canadian Dollar to double RUBY-FILL capacity
-
Jubilant Pharmova's arm to invest 94.5 million Canadian Dollar to double RUBY-FILL capacity
-
Jubilant Pharmova board to consider raising funds via NCDs on Oct 12 - scanx.trade
-
Jubilant Pharmova Receives Rs 87-Cr GST Demand Notice
-
Jubilant Pharmova gets USFDA's approval for new Isolator based fill and finish line at Spokane Facility
-
Jubilant Pharmova jumps on getting USFDA's approval for new Isolator based fill and finish line at Spokane Facility
-
Stocks to watch: ZEEL, Vodafone Idea, Jubilant Pharmova, Power Grid, BoB - Business Standard
Frequently Asked Questions
What is Jubilant Pharmova's current stock price?
Jubilant Pharmova shares were last quoted at ₹957.50 (+2.7% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Jubilant Pharmova?
Jubilant Pharmova has a price-to-earnings (P/E) ratio of 48.58 and a price-to-book (P/B) ratio of 2.40. The industry P/E is 53.33.
What is the 52-week high and low of Jubilant Pharmova?
The 52-week high of Jubilant Pharmova is ₹1,183.90 and the 52-week low is ₹783.75.
What is the market cap of Jubilant Pharmova?
The market capitalisation of Jubilant Pharmova is about ₹17,109.18 crore.
How did Jubilant Pharmova perform in its latest quarterly results?
In the latest quarter (Jun 2026), Jubilant Pharmova reported sales of ₹2,229.00 crore (+17.3%) and net profit of ₹56.00 crore (-45.1%), compared with the same quarter last year.
Is Jubilant Pharmova a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Jubilant Pharmova has a 3-year ROE of 5.00%, 3-year profit growth of 47.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Jubilant Pharmova?
Promoters hold about 47.68% of Jubilant Pharmova.
Which sector does Jubilant Pharmova belong to?
Jubilant Pharmova belongs to the Pharmaceuticals & Drugs sector.